♦ Coronavirus Spike Mutants
Since emerging in 2019, SARS-CoV-2’s genome has proved to be relatively stable. However, the emergence of multiple new variants in late 2020 has caused concern over the efficacy of recently-developed countermeasures, including diagnostics, therapeutics and vaccines. Many mutations have occurred in the Spike protein and its receptor-binding domain (RBD), which plays a central role in pathogenesis and the induction of neutralising antibodies. To identify and investigate the effects of these mutations, extensive work is now underway.
♦ Our Mutant Pipeline
To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of mutant Spike antigens. Expressed from our proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.
♦ Spike Mutation Map
The map below shows all the Spike mutations we currently provide or are developing in relation to the original Wuhan-Hu-1 sequence: